http://www.neptunebiotech.com/products I first heard about this stock
when it was trading at the $2.32 mark a few weeks ago. Now we're hearing that more institutional buying and high profile firms are getting ready to take positions. That, in-turn, should lead to even more buying by retail investors. It's the stock snowball and visibility effect and this company deserves it
Neptune Technologies & Bioressources Inc. researches, develops and commercializes proprietary bioactive ingredients and products with superior added-value and clinically proven health benefits. The Company extracts a range of bioactive ingredients such as novel proprietary omega-3 phospholipids from abundant yet underexploited marine biomass including Krill, a cold deep water zooplankton. Neptune's first commercially available product is Neptune Krill Oil (NKO®), which represents the only clinically proven and scientifically acknowledged marine omega-3 phospholipids with cardiovascular, cognitive and anti-inflammatory benefits for human applications and which exhibits unmet safety, purity and stability and consequently denoting a new level of excellence in omega-3 standards.
Neptune is pursuing market opportunities in the nutraceutical market including dietary supplements and functional foods. The Company is benefiting from opportunities in the pharmaceutical market through its pharmaceutical subsidiaries Acasti Pharma and NeuroBioPharm (including medical food, over-the-counter and prescription drug applications).
The Mission of Neptune is to:
- Research, Develop and Commercialize Novel Marine Bioactive Ingredients
- Pursue opportunities in the nutraceutical markets
- Dietary Supplement
- Functional Food
- Exploit pharmaceutical applications
- Subsidiary Acasti Pharma Inc: Cardiovascular diseases
- Subsidiary NeuroBioPharm Inc.: Neurodegenerative diseases
- Validate Superiority, Safety & Effectiveness
- Protect Intellectual Property
- Enter Commercialization Alliances and Partnership Licenses
Promising results from A new cholesterol drug have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.
The Versant Partners' report, subtitled: "Krill oil franchise poised to outperform in multiple consumer and medical markets" features a few key points of note.
With NEPT's fiscal year end being February, Mr. Loe is calling for:
* F2012 revenues of $21.79 million and earnings $4.34 million ($0.09 EPS)
* F2013 revenues of $32.39 million and earnings of $8.81 million ($0.17 EPS)
* F2014 revenues of $45.37 million and earnings of $15.69 million ($0.30 EPS)
Loe cited management plans to meet forecasted demand by increasing current plant production from 130 thousand kilograms of krill oil per year to 430 thousand kilograms per year by 2015, a 300% production increase.
The report pinned its share price targets not only on the business Neptune has in hand, but also its future. By far, the biggest foundation Mr. Loe constructed on which to base his conclusions came from his meticulous research into the product itself - Neptune Krill Oil or NKO as it is branded on the market - and all its further refined products, such as Acasti's drug candidate called 'CaPre'.
Along the way, Loe also gives a significant nod to the functional food alliances Neptune developed with Yoplait - which is 50% owned by General Mills - and the food manufacturing behemoth, Nestle.
Mr. Loe wrote that both Yoplait and Nestle "should conclude development," of their research into Neptune Krill Oil by the end of the current year and that assuming all goes well, the sales of krill-oil infused food products by these giants would be a major revenue driver for Neptune in 2013/14 About Acasti
Acasti Pharma is developing safe and effective pharmaceutical and medical applications with an initial focus on cardiovascular disease by leveraging the intellectual property, clinical data and know how developed by Neptune Technologies. The Company is advancing a portfolio of bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway which includes prescription medical foods (MF), over-the-counter products (OTC), and prescription drugs (Rx). Phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux.
Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) stabilized by potent antioxidants. Evidence has demonstrated the anti-inflammatory properties of EPA and DHA regulating important biological functions including degenerative, arthritic, circulatory, digestive, and brain diseases. Delivering omega-3s functionalized on phospholipids helps optimize the omega-3 fatty acid therapeutic benefits. Potent antioxidants contribute to proper physiological regulation preventing free radical cellular damage, a common pathway for cardiovascular disease and inflammation as well as neurodegenerative disease